C57BL/6NCya-Siglec15em1/Cya
Common Name:
Siglec15-KO
Product ID:
S-KO-11239
Background:
C57BL/6NCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Siglec15-KO
Strain ID
KOCMP-620235-Siglec15-B6N-VA
Gene Name
Product ID
S-KO-11239
Gene Alias
Cd33l3; EG620235; SIGLEC-I
Background
C57BL/6NCya
NCBI ID
Modification
Conventional knockout
Chromosome
18
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6NCya-Siglec15em1/Cya mice (Catalog S-KO-11239) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000170760
NCBI RefSeq
NM_001101038
Target Region
Exon 2~5
Size of Effective Region
~3.2 kb
Detailed Document
Overview of Gene Research
Siglec15, a sialic acid-binding immunoglobulin-like lectin, has emerged as a significant molecule in the immune-tumor interaction landscape. It is involved in immune evasion mechanisms, mainly by suppressing T lymphocyte activation and proliferation, and is also implicated in osteoclast differentiation and bone remodeling [2]. In the tumor microenvironment (TME), it can shape a non-inflamed state, influencing cancer progression and response to immunotherapy.
In bladder cancer, overexpression of Siglec15 leads to reduced CD8+ T cell infiltration by downregulating pro-inflammatory cytokines and chemokines, exacerbating malignancy and contributing to immune evasion [6]. In breast cancer, osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting secondary metastasis [1]. In anaplastic thyroid cancer, blocking Siglec15 with an antibody increases the cytotoxic ability of CD8+ T cells, inhibits tumor growth, and prolongs mouse survival [3]. In pancreatic cancer, Siglec15+ tumor-associated macrophages (TAMs) present an M2-like phenotype, accelerating tumor growth and immunosuppressive microenvironment [4]. In hepatocellular carcinoma, Siglec15 promotes immune evasion by inducing CD8+ T cell apoptosis [5]. In non-small cell lung cancer, Siglec15 knockdown inhibits cell proliferation, migration, and invasion, and down-regulation of Siglec15 in tumor cells enhances the antitumor immune responses of CD8+ T cells [7].
In conclusion, Siglec15 plays a crucial role in immune evasion and tumor progression across multiple cancer types. Mouse models, especially those involving gene knockout (KO) or conditional knockout (CKO) of Siglec15, have been instrumental in revealing its functions in specific disease conditions, highlighting its potential as a therapeutic target for cancer immunotherapy.
References:
1. Wu, Yutong, Ai, Hongbo, Xi, Yuhang, Luo, Fei, Dou, Ce. 2023. Osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting breast cancer secondary metastasis. In Cell reports. Medicine, 4, 101165. doi:10.1016/j.xcrm.2023.101165. https://pubmed.ncbi.nlm.nih.gov/37607544/
2. Fan, Yujia, Sun, Liangliang, He, Juan, Ma, Hongli, Ding, Haitao. 2024. Siglec15 in blood system diseases: from bench to bedside. In Frontiers in immunology, 15, 1490505. doi:10.3389/fimmu.2024.1490505. https://pubmed.ncbi.nlm.nih.gov/39697338/
3. Bao, Lisha, Li, Ying, Hu, Xiaoping, Ge, Minghua, Pan, Zongfu. 2024. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer. In International immunopharmacology, 133, 112102. doi:10.1016/j.intimp.2024.112102. https://pubmed.ncbi.nlm.nih.gov/38652971/
4. Li, Tian-Jiao, Jin, Kai-Zhou, Li, Hao, Yu, Xian-Jun, Wu, Wei-Ding. 2022. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. In Cancer letters, 530, 142-155. doi:10.1016/j.canlet.2022.01.026. https://pubmed.ncbi.nlm.nih.gov/35077803/
5. Chen, Zheng, Yu, Mincheng, Zhang, Bo, Li, Hui, Guo, Lei. 2024. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. In Oncoimmunology, 13, 2376264. doi:10.1080/2162402X.2024.2376264. https://pubmed.ncbi.nlm.nih.gov/38988824/
6. Deng, Dingshan, Xiao, Jiatong, Liu, Jinhui, Hu, Jiao, Zu, Xiongbing. 2024. Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer. In Journal of hematology & oncology, 17, 117. doi:10.1186/s13045-024-01638-2. https://pubmed.ncbi.nlm.nih.gov/39609852/
7. Liang, Haifeng, Chen, Qing, Hu, Zhichao, Jiang, Libo, Dong, Jian. . Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis. In Annals of translational medicine, 10, 281. doi:10.21037/atm-22-764. https://pubmed.ncbi.nlm.nih.gov/35434017/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen